Barclays analyst Luke Sergott initiated coverage of Qiagen (QGEN) with an Overweight rating and $55 price target The firm says Qiagen screens positive among tools given its exposure to diagnostics and higher growth genomics markets on the life sciences side. In the current macro and policy-driven space, Barclays favors diagnostics given the minimal exposure to headwinds plaguing the overall industry including biotech funding and pharma tariffs. On genomics, volumes in the business continue to be supported by cutting-edge research and increasingly by clinical applications like liquid biopsy, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Qiagen Announces BlackRock’s Significant Voting Rights Disclosure
- Qiagen’s Voting Rights Notification Highlights BlackRock’s Influence
- BlackRock’s Significant Stake in Qiagen Revealed
- Qiagen, Gencurix announce oncology assay partnership
- Qiagen, Incyte announce collaboration to develop companion diagnostics